Abstract:Oral insulin delivery has received the most attention in insulin formulations due to its high patient compliance and, more importantly, to its potential to mimic the physiologic insulin secretion seen in non-diabetic individuals. However, oral insulin delivery has two major limitations: the enzymatic barrier that leads to rapid insulin degradation, and the mucosal barrier that limits insulin’s bioavailability. Several approaches have been actively pursued to circumvent the enzyme barrier, with some of them receiving promising results. Yet, thus far there has been no major success in overcoming the mucosal barrier, which is the main cause in undercutting insulin’s oral bioavailability. In this review of our group’s research, an innovative silica-based, mucoadhesive oral insulin formulation with encapsulated-insulin/cell penetrating peptide (CPP) to overcome both enzyme and mucosal barriers is discussed, and the preliminary and convincing results to confirm the plausibility of this oral insulin delivery system are reviewed. In vitro studies demonstrated that the CPP-insulin conjugates could facilitate cellular uptake of insulin while keeping insulin’s biologic functions intact. It was also confirmed that low molecular weight protamine (LMWP) behaves like a CPP peptide, with a cell translocation potency equivalent to that of the widely studied TAT. The mucoadhesive properties of the produced silica-chitosan composites could be controlled by varying both the pH and composition; the composite consisting of chitosan (25 wt-%) and silica (75 wt-%) exhibited the greatest mucoadhesion at gastric pH. Furthermore, drug release from the composite network could also be regulated by altering the chitosan content. Overall, the universal applicability of those technologies could lead to development of a generic platform for oral delivery of many other bioactive compounds, especially for peptide or protein drugs which inevitably encounter the poor bioavailability issues.

Lipophilic Salts and Lipid-Based Formulations: Enhancing the Oral Delivery of Octreotide

Systemic delivery of peptides by the oral route: Formulation and medicinal chemistry approaches

Lipid-Based Nanoparticles as Oral Drug Delivery Systems: Overcoming Poor Gastrointestinal Absorption and Enhancing Bioavailability of Peptide and Protein Therapeutics

Recent progress in hydrophobic ion-pairing and lipid-based drug delivery systems for enhanced oral delivery of biopharmaceuticals

Recent Advances in Oral Peptide or Protein-Based Drug Liposomes

Oral peptide and protein delivery: intestinal obstacles and commercial prospects

Oral Delivery of the Vancomycin Derivative FU002 by a Surface‐Modified Liposomal Nanocarrier

Oral delivery of protein and peptide drugs: from non-specific formulation approaches to intestinal cell targeting strategies

Systemic delivery of proteins using novel peptides via the sublingual route

In vitro and in vivo evaluation of positively charged liposaccharide derivatives as oral absorption enhancers for the delivery of anionic drugs

Advances in Lipid-Based Drug Delivery: Enhancing Efficiency for Hydrophobic Drugs

Tableting lipid-based formulations for oral drug delivery: a case study with silica nanoparticle-lipid-mannitol hybrid microparticles

Delivery of Oligonucleotides: Efficiency with Lipid Conjugation and Clinical Outcome

A Window for Enhanced Oral Delivery of Therapeutics via Lipid Nanoparticles

Lipid-Based Drug Delivery System (LBDDS): An Emerging Paradigm to Enhance Oral Bioavailability of Poorly Soluble Drugs

Challenges of peptide and protein drug delivery by oral route: Current strategies to improve the bioavailability

Long-acting injectable formulation technologies: challenges and opportunities for the delivery of fragile molecules

Overcoming Oral Insulin Delivery Barriers: Application of Cell Penetrating Peptide and Silica-Based Nanoporous Composites

Optimisation of a Microfluidic Method for the Delivery of a Small Peptide

Strategies for Improving Peptide Stability and Delivery

Gastrointestinal Permeation Enhancers for the Development of Oral Peptide Pharmaceuticals